ZTSHIGH SIGNALFINANCIAL10-K

ZTS shows concerning financial deterioration with stockholders' equity declining 30% while total liabilities surge 28%, despite strong revenue growth and dramatically increased share buybacks.

The combination of declining equity, rising liabilities, and massive increase in share buybacks suggests potential overleveraging or aggressive capital allocation that may be compromising the balance sheet. While revenue grew modestly, the 74% increase in buybacks to $3.2B appears to be funded through debt or cash depletion, raising questions about capital allocation priorities and financial sustainability.

Comparing 2026-02-12 vs 2025-02-13View on EDGAR →
FINANCIAL ANALYSIS

ZTS demonstrates mixed financial signals with positive operational momentum (revenue up to $9.4B, cash more than doubling to $1.6B) but concerning balance sheet deterioration. The 30% decline in stockholders' equity combined with a 28% increase in total liabilities, alongside dramatically increased share buybacks of $3.2B, suggests aggressive financial engineering that may be creating leverage risks. The overall picture indicates strong operational performance being overshadowed by potentially unsustainable capital allocation decisions that warrant close investor scrutiny.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+115.1%
$727.0M$1.6B

Cash position surged 115.1% — strong cash generation or capital raise providing significant financial cushion.

Share Buybacks
Cash Flow
+74.1%
$1.9B$3.2B

Share repurchases increased 74.1% — management returning capital, signals confidence in intrinsic value.

Current Liabilities
Balance Sheet
-34.5%
$3.4B$2.2B

Current liabilities reduced — improved short-term financial position and working capital health.

Stockholders Equity
Balance Sheet
-30.2%
$4.8B$3.3B

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Total Liabilities
Balance Sheet
+28.2%
$9.5B$12.1B

Liabilities increased 28.2% — monitor debt-to-equity ratio and interest coverage.

Accounts Receivable
Balance Sheet
+20.8%
$1.3B$1.6B

Receivables grew 20.8% — monitor days sales outstanding for collection efficiency.

Current Assets
Balance Sheet
+13.1%
$6.0B$6.8B

Current assets grew 13.1% — improving short-term liquidity or inventory/receivables build.

LANGUAGE CHANGES
NEW — 2026-02-12
PRIOR — 2025-02-13
ADDED
With a legacy of nearly 75 years, we continue to pioneer ways to predict, prevent, detect, and treat animal illness, supporting those raising and caring for animals worldwide - from veterinarians and pet owners to livestock producers.
As a result of these differences, among other things, we organize and operate our business in two segments: United States (U.S.) with revenue of $5,097 million, or 54% of total revenue for the year ended December 31, 2025; and International with revenue of $4,254 million, or 45% of total revenue for the year ended December 31, 2025.
In 2026, we expect to eliminate the one-month lag in reporting of our subsidiaries operating outside the U.S.
and align the fiscal years of the subsidiaries within our U.S.
segment and the subsidiaries within our International segment.
+7 more — sign up free →
REMOVED
For over 70 years, we have been innovating ways to predict, prevent, detect, and treat animal illness, and continue to stand by those raising and caring for animals worldwide - from veterinarians and pet owners to livestock producers.
As a result of these differences, among other things, we organize and operate our business in two segments: United States (U.S.) with revenue of $5,074 million, or 55% of total revenue for the year ended December 31, 2024; and International with revenue of $4,102 million, or 44% of total revenue for the year ended December 31, 2024.
Companion animal products represented approximately 68% of our revenue for the year ended December 31, 2024.
Livestock products represented approximately 31% of our revenue for the year ended December 31, 2024.
For example, the first product in our ceftiofur line was an anti-infective approved for treating bovine respiratory disease (BRD) in cattle that was administered via intramuscular injection.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →